The scavenger receptor class B, type i is a primary determinant of paraoxonase-1 association with high-density lipoproteins

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 11, 2010, Pages 2121-2127

  James, Richard W ^a   Brulhart Meynet, Marie Claude ^a   Singh, Anurag Kumar ^b   Riederer, Brigitte ^b   Seidler, Ursula ^b   Out, Ruud ^c   Van Berkel, Theo J C ^c   Deakin, Sara ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

atherosclerosis; high density lipoproteins; oxidative stress; scavenger receptor

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; BLOCK LIPID TRANSPORT 1; CARRIER PROTEIN; HIGH DENSITY LIPOPROTEIN; POSTSYNAPTIC DENSITY PROTEIN 95; SCAVENGER RECEPTOR BI; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL STRAIN HEPG2; CHO CELL; CORRELATIONAL STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME RELEASE; FEMALE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; LIPOPROTEIN METABOLISM; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; CELLS, CULTURED; CRICETINAE; DOWN-REGULATION; GENE EXPRESSION; HUMANS; LIPOPROTEINS, HDL; SCAVENGER RECEPTORS, CLASS B;

EID: 78149282921     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.209122     Document Type: Article

References (26)

1. Shih DM, Gu L, Xia Y-R, Navab M, Li W-F, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284-287.
2. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, Cheroutre H, Faull KF, Berliner JA, Witztum JL, Lusis AJ. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem. 2000;275:17527-17535.
3. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan ML, Allayee H, Lusis AJ, Hazen SL. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008;299:1265-1276.
4. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, Mackness M. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 2003;107:2775-2779.
5. Deakin S, Leviev I, Gomaraschi M, Calabresi L, Franceschini G, James RW. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem. 2002;277:4301-4308.
6. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol. 1999;19:2214-2225.
7. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM. Mechanisms of disease: proatherogenic HDL: an evolving field. Nature Clin Pract Endocrinol Metab. 2006;2:504-511.
8. Blatter M-C, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45: identity of K-45 with paraoxonase. Eur J Biochem. 1993;211:871-879.
9. Connelly PW, Maguire GF, Picardo CM, Teiber JF, Draganov D. Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma. J Lipid Res. 2008;49:245-250.
10. Hillesheim J, Riederer B, Tuo B, Chen M, Manns M, Biber J, Yun C, Kocher O, Seidler U. Down regulation of small intestinal ion transport in PDZK1-(CAP70/NHERF3) deficient mice. Pflugers Arch. 2007;454:575-586.
11. Sjöblom M, Singh AK, Zheng W, Wang J, Tuo BG, Krabbenhöft A, Riederer B, Gros G, Seidler U. Duodenal acidity "sensing" but not epithelial HCO3-supply is critically dependent on carbonic anhydrase II expression. Proc Natl Acad Sci. 2009;106:13094-13099.
12. Deakin S, Moren X, James RW. Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells. Atherosclerosis. 2005;179:17-25.
13. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996;271:518-520.
14. Krieger M. Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem. 1999;68:523-558.
15. Nieland TJ, Shaw JT, Jaipuri FA, Duffner JL, Koehler AN, Banakos S, Zannis VI, Kirchhausen T, Krieger M. Identification of the molecular target of small molecule inhibitors of HDL receptor SR-BI activity. Biochemistry. 2008;47:460-472.
16. Kocher O, Krieger M. Role of the adaptor protein PDZK1 in controlling the HDL receptor SR-BI. Curr Opin Lipidol. 2009;20:236-241.
17. Out R, Hoekstra M, Meurs I, de Vos P, Kuiper J, Van Eck M, Van Berkel TJ. Total body ABCG1 expression protects against early atherosclerotic lesion development in mice. Arterioscler Thromb Vasc Biol. 2007;27:594-599.
18. Van Eck M, Hoekstra M, Hildebrand RB, Yaong Y, Stengel D, Kruijt JK, Sattler W, Tietge UJ, Ninio E, Van Berkel TJ, Praticò D. Increased oxidative stress in scavenger receptor BI knockout mice with dysfunctional HDL. Arterioscler Thromb Vasc Biol. 2007;27:2413-2419.
19. Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation. 2001;103:2283-2288.
20. Navab M, Reddy S, Van Lenten BJ, Anantharamaiah GM, Fogelman AM. Role of dysfunctional HDL in atherosclerosis. J Lipid Res. 2008;50:S145-S149.
21. Calvo D, Gómez-Coronado D, Lasunción MA, Vega MA. CLA-1 is an 85-kD plasma membrane glycoprotein that acts as a high-affinity receptor for both native (HDL, LDL, and VLDL) and modified (OxLDL and AcLDL) lipoproteins. Arterioscler Thromb Vasc Biol. 1997;17:2341-2349.
22. Nieland TJ, Penman M, Dori L, Krieger M, Kirchhausen T. Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI. Proc Natl Acad Sci U S A. 2002;99:15422-15427.
23. Kocher O, Yesilaltay A, Cirovic C, Pal R, Rigotti A, Krieger M. Targeted disruption of the PDZK1 gene in mice causes tissue-specific depletion of the high density lipoprotein receptor scavenger receptor class B type I and altered lipoprotein metabolism. J Biol Chem. 2003;278:52820-52825.
24. Navab M, Hama-Levy S, Van Lenten B, Fonarow GC, Cardinez CJ, Castellani LW, Brennan M-L, Lusus AJ, Fogelman AM. Mildly oxidised LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest. 1997;99:2005-2019.
25. Tölle M, Pawlak A, Schuchardt M, Kawamura A, Tietge UJ, Lorkowski S, Keul P, Assmann G, Chun J, Levkau B, van der Giet M, Nofer JR. HDL-associated lysosphingolipids inhibit NAD (P) H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol. 2008;28:1542-1548.
26. Trigatti BL, Krieger M, Rigotti A. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:1732-1738.